Gene · 325
Papers4,193
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 4,193
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Pathogenic Role of Dysregulated Epigenetic Modifications in Autoimmune Diseases. | Front Immunol | 2019 | 31611879 | PubTator, text mining | PubMed |
| Inflamm-Aging Is Associated with Lower Plasma PTX3 Concentrations and an Impaired Capacity of PBMCs to Express hTERT following LPS Stimulation. | Mediators Inflamm | 2019 | 31611733 | PubTator, text mining | PubMed |
| DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. | Clin Epigenetics | 2019 | 31601247 | PubTator, text mining | PubMed |
| Circulating pentraxin-3 levels in patients with systemic lupus erythematosus: a meta-analysis. | Biomark Med | 2019 | 31599644 | PubTator, text mining | PubMed |
| Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. | Circulation | 2019 | 31597453 | PubTator, text mining | PubMed |
| SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. | Sci Rep | 2019 | 31594956 | PubTator, text mining | PubMed |
| Pyruvate Substitutions on Glycoconjugates. | Int J Mol Sci | 2019 | 31590345 | PubTator, text mining | PubMed |
| Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. | Pol Arch Intern Med | 2019 | 31566590 | PubTator, text mining | PubMed |
| Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Authors' reply. | Pol Arch Intern Med | 2019 | 31566589 | PubTator, text mining | PubMed |
| SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. | J Cell Mol Med | 2019 | 31560832 | PubTator, text mining | PubMed |
| Role of pentraxin-3 in risk assessment of patients with metabolic syndrome. | Physiol Int | 2019 | 31560233 | PubTator, text mining | PubMed |
| Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. | Int J Environ Res Public Health | 2019 | 31554274 | PubTator, text mining | PubMed |
| Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. | ESC Heart Fail | 2019 | 31553132 | PubTator, text mining | PubMed |
| Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting. | Clin Adv Hematol Oncol | 2019 | 31545309 | PubTator, text mining | PubMed |
| Serum Amyloid P and a Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin Ligand Inhibit High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice. | Am J Pathol | 2019 | 31539521 | PubTator, text mining | PubMed |
| PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma. | Int J Mol Sci | 2019 | 31533326 | PubTator, text mining | PubMed |
| C-reactive protein/serum amyloid P promotes pro-inflammatory function and induces M1-type polarization of monocytes/macrophages in mudskipper, Boleophthalmus pectinirostris. | Fish Shellfish Immunol | 2019 | 31513914 | PubTator, text mining | PubMed |
| Myelofibrosis in 2019: moving beyond JAK2 inhibition. | Blood Cancer J | 2019 | 31511492 | PubTator, text mining | PubMed |
| What have we learned from basic science studies on idiopathic pulmonary fibrosis? | Eur Respir Rev | 2019 | 31511255 | PubTator, text mining | PubMed |
| Expression, Role, and Regulation of Neutrophil Fcγ Receptors. | Front Immunol | 2019 | 31507592 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/325/papers?page=60